- Home
- KYMR vs ATAT Comparison
KYMR vs ATAT Comparison
Compare KYMR & ATAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KYMR | ATAT |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 5.9B |
| IPO Year | 2020 | 2022 |
Fundamental Metrics
Financial Performance| Metric | KYMR | ATAT |
|---|---|---|
| Price | $73.32 | $40.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 24 | 5 |
| Target Price | ★ $105.35 | $46.16 |
| AVG Volume (30 Days) | 916.5K | ★ 979.4K |
| Earning Date | 02-26-2026 | 11-25-2025 |
| Dividend Yield | N/A | ★ 1.14% |
| EPS Growth | N/A | ★ 25.36 |
| EPS | N/A | ★ 1.48 |
| Revenue | $43,735,000.00 | ★ $1,276,315,178.00 |
| Revenue This Year | $18.71 | $37.82 |
| Revenue Next Year | N/A | $23.56 |
| P/E Ratio | ★ N/A | $26.80 |
| Revenue Growth | N/A | ★ 36.24 |
| 52 Week Low | $19.45 | $21.50 |
| 52 Week High | $103.00 | $43.17 |
Technical Indicators
Market Signals| Indicator | KYMR | ATAT |
|---|---|---|
| Relative Strength Index (RSI) | 44.55 | 46.80 |
| Support Level | $73.71 | $40.25 |
| Resistance Level | $77.93 | $42.79 |
| Average True Range (ATR) | 3.17 | 1.49 |
| MACD | -1.40 | -0.18 |
| Stochastic Oscillator | 25.96 | 26.49 |
Price Performance
Historical ComparisonAbout KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
About ATAT Atour Lifestyle Holdings Limited
Atour Lifestyle Holdings Ltd is an upper-midscale hotel chain in China. The company derives revenues from franchise and management fees from its manachised hotels and sales of hotel supplies to manachised hotels, Operations of leased hotels, and sales of retail products. The company has one operating segment, which is the Atour Group.